Xenon Pharmaceuticals IncNASDAQ XENE Stock Report

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 203 full-time employees. The company went IPO on 2014-10-17. The firm is focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The firm is focused on advancing its ion channel neurology pipeline. The firm's products within its novel proprietary pipeline include clinical-stage candidates XEN496 and XEN1101, which are focused on treating neurological disorders, with a particular focus on epilepsy. XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). The XEN496 is a Kv7 potassium channel opener, is a pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy, or KCNQ2-DEE. The firm has promising partnered products within its pipelines, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.